CLRB - Cellectar Biosciences, Inc.

2.56
-0.050   -1.953%

Share volume: 21,597
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.12%

PREVIOUS CLOSE
CHG
CHG%
$2.61
-0.05
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 25%
Dept financing 6%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-7.25%
1 Month
-1.92%
3 Months
-20.99%
6 Months
-23.58%
1 Year
779.73%
2 Year
-17.42%
Key data
Stock price
$2.56
P/E Ratio 
N/A
DAY RANGE
$2.55 - $2.83
EPS 
-$6.97
52 WEEK RANGE
$0.23 - $10.19
52 WEEK CHANGE
$917.49
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
4.240 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
1.98
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$18,485
AVERAGE 30 VOLUME 
$29,971
Company detail
CEO: James V. Caruso
Region: US
Website: cellectar.com
Employees: 10
IPO year: 2005
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Cellectar Biosciences, Inc. focuses on the discovery, development, and commercialization of drugs for cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies.

Recent news